Literature DB >> 28342276

Primary cutaneous anaplastic large cell lymphoma.

Ryanne A Brown1, Sebastian Fernandez-Pol1, Jinah Kim1,2.   

Abstract

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease. CD30+ LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides. Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990CD30+ lymphoproliferative disorder; primary cutaneous anaplastic large cell lymphoma

Mesh:

Substances:

Year:  2017        PMID: 28342276     DOI: 10.1111/cup.12937

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  11 in total

Review 1.  Update on the Treatment of Anaplastic Large Cell Lymphoma.

Authors:  Khoan Vu; Weiyun Ai
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

2.  Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.

Authors:  Stephan Mathas; Lukas Kenner; Olaf Merkel; Huan-Chang Liang; Mariantonia Costanza; Nicole Prutsch; Mark W Zimmerman; Elisabeth Gurnhofer; Ivonne A Montes-Mojarro; Brian J Abraham; Nina Prokoph; Stefan Stoiber; Simone Tangermann; Cosimo Lobello; Jan Oppelt; Ioannis Anagnostopoulos; Thomas Hielscher; Shahid Pervez; Wolfram Klapper; Francesca Zammarchi; Daniel-Adriano Silva; K Christopher Garcia; David Baker; Martin Janz; Nikolai Schleussner; Falko Fend; Šárka Pospíšilová; Andrea Janiková; Jacqueline Wallwitz; Dagmar Stoiber; Ingrid Simonitsch-Klupp; Lorenzo Cerroni; Stefano Pileri; Laurence de Leval; David Sibon; Virginie Fataccioli; Philippe Gaulard; Chalid Assaf; Fabian Knörr; Christine Damm-Welk; Wilhelm Woessmann; Suzanne D Turner; A Thomas Look
Journal:  Nat Commun       Date:  2021-09-22       Impact factor: 17.694

3.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

4.  Primary Cutaneous Anaplastic Large-Cell Lymphoma.

Authors:  Nerissa Moodley; Patiswa Nombona; Anisa Mosam
Journal:  Dermatopathology (Basel)       Date:  2019-06-26

5.  Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma: A Rare Association With Large Plaque Parapsoriasis.

Authors:  Ionela Manole; Alexandra-Irina Butacu; Iulia-Elena Negulet; Marius-Cristian Valcoci; George-Sorin Tiplica
Journal:  Cureus       Date:  2020-10-28

6.  Dermoscopy of Primary Cutaneous Anaplastic Lymphoma Kinase Negative Large T-Cell Lymphoma.

Authors:  Keshavmurthy A Adya; Ajit B Janagond; Arun C Inamadar; Satish Arakeri
Journal:  Indian Dermatol Online J       Date:  2022-03-03

7.  Primary Lymphomas of the Breast: A Review.

Authors:  Emily R James; Roberto N Miranda; Suzanne D Turner
Journal:  JPRAS Open       Date:  2022-02-20

Review 8.  Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Authors:  Xin-Rui Zhang; Pham-Ngoc Chien; Sun-Young Nam; Chan-Yeong Heo
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

Review 9.  Anaplastic Lymphoma Kinase in Cutaneous Malignancies.

Authors:  Severine Cao; Vinod E Nambudiri
Journal:  Cancers (Basel)       Date:  2017-09-12       Impact factor: 6.639

Review 10.  Cutaneous T-cell lymphomas in the revised 4th edition of World Health Organization classification of tumors of hematopoietic and lymphoid tissues (2017).

Authors:  Jose Candido Caldeira Xavier Júnior; Juliana Polizel Ocanha-Xavier
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.